Eli Lilly (LLY) Long-Term Deferred Tax (2017 - 2026)

Eli Lilly has reported Long-Term Deferred Tax for 10 years, with the latest figure at $11.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 32.39% year-over-year to $11.4 billion; the trailing twelve-month figure through Mar 2026 stood at $11.4 billion (up 32.39% YoY), and the FY2025 full-year result was $10.0 billion, up 24.47% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $11.4 billion, up from $10.0 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $11.4 billion in Q1 2026, with the low at $2.4 billion in Q2 2022.
• Historically, Long-Term Deferred Tax has averaged $6.1 billion across 5 years, with a median of $5.6 billion in 2024.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax fell 11.33% — and 2023, when it soared 96.12%.
• Eli Lilly's Long-Term Deferred Tax stood at $2.8 billion in 2022, then surged by 96.12% to $5.5 billion in 2023, then soared by 46.08% to $8.0 billion in 2024, then climbed by 24.47% to $10.0 billion in 2025, then advanced by 13.97% to $11.4 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $11.4 billion (Q1 2026), $10.0 billion (Q4 2025), and $9.0 billion (Q3 2025), per Business Quant data.